At the dawn of potent therapeutics for fatty liver disease - introducing the miniseries on promising pharmacological targets for NASH

J Hepatol. 2023 Aug;79(2):261-262. doi: 10.1016/j.jhep.2023.04.003.

Authors

Vlad Ratziu¹, Frank Tacke²

Affiliations

¹ Sorbonne Université, Institute for Cardiometabolism and Nutrition, Hospital Pitié Salpêtrière, Assistance Publique-Hôpitaux de Paris, Paris, France. Electronic address: vlad.ratziu@inserm.fr.
² Charité - Universitätsmedizin Berlin, Department of Hepatology and Gastroenterology, Campus Virchow-Klinikum (CVK) and Campus Charité Mitte (CCM), Berlin, Germany. Electronic address: frank.tacke@charite.de.

PMID: 37455046
DOI: 10.1016/j.jhep.2023.04.003

No abstract available

Publication types

Editorial
Comment

MeSH terms

Humans
Hypoglycemic Agents
Liver
Non-alcoholic Fatty Liver Disease* / drug therapy

Substances

Hypoglycemic Agents